Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

A global standard for the testing of mycoplasma contamination has been developed

17.06.2015

Biological medicinal products such as recombinant proteins, monoclonal antibodies, and many vaccines are produced in cell cultures. Specific detection assays are performed, to make sure that these products are not contaminated with pathogens. Staff members of the Paul-Ehrlich-Institut have taken the lead in developing, on behalf of the WHO, the first internationally recognized reference preparation for tests detecting mycoplasma contamination in cell cultures. The journal “Applied and Environmental Microbiology” reports on this newly developed WHO standard in its online edition of 12 June 2015.
doi:10.1128/AEM.01150-15

Mycoplasma is a genus of very small bacteria that lack a cell wall. Due to their very small size and their flexible shape, these pathogens are able to pass bacteria filters and, for this reason cannot be safely removed by means of such filters during the manufacture of medicinal products. Mycoplasma include species which cause diseases of the respiratory and urogenital tracts in humans.


Mycoplasma-contaminated cell culture

Prof. Dr. Renate Rosengarten, University of Veterinary Medicine, Vienna & Mycoplasma Biosafety Services GmbH

Various test methods are applied to ascertain that neither the original cells used for the production of biological medicinal products – the so-called master cell banks – nor the production cells themselves are contaminated with mycoplasma bacteria.

One of the most sensitive test methods is the nucleic acid amplification technique (NAT). It involves amplification of sections of the bacterial genome by a billion, enabling the detection of the pathogenic agent. As with other test methods, a prerequisite for test reliability is its verification using suitable reference materials – so-called WHO International Standards (IS).

Coworkers of PD Dr Micha Nübling, head of the Section Molecular Virology of the Division Virology at the Paul-Ehrlich-Institut, have developed the first IS for NAT testing for mycoplasma (“1st WHO IS for mycoplasma DNA for NAT assay designed for generic mycoplasma detection”).

The Section at the PEI forms part of the WHO Collaborating Centre for Quality Assurance of Blood Products and in vitro Diagnostic Devices at the institute. Part of the development process of the IS involved an international feasibility study, in which four distantly related mycoplasma species were assayed in different concentrations by 21 laboratories using 26 NAT methods.

Based on the results obtained from these studies, the WHO standard was designed and manufactured and finally established by the WHO “Expert Committee on Biological Standardization (ECBS)”. Professor Klaus Cichutek, president of the Paul-Ehrlich-Institut, is a member of the ECBS.

This WHO IS is now available for the determination of quality features of NAT tests (e.g. the detection limit), the calibration of quantitative assays and the definition of regulatory requirements for mycoplasma testing. “We are pleased that we have succeeded in developing this WHO standard, which will contribute to making worldwide test methods for the detection of mycoplasmas - more reliable and comparable with each other“, says PD Dr Micha Nübling.

Original Publication
Nübling CM, Baylis SA, Hanschmann KM, Montag-Lessing T†,
Chudy M, Kreß J, Ulrych U, Czurda S, Rosengarten R, and
the Mycoplasma Collaborative Study Group (2015): World Health Organization International Standard to Harmonize Assays for Detection of Mycoplasma DNA. Appl Environ Microbiol. 2015 Jun 12. pii: AEM.01150-15
doi:10.1128/AEM.01150-15


The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines in Langen near Frankfurt/Main, is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and veterinary vaccines. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the varied and many tasks performed at the institute. The PEI, with its roughly 800 staff, also has advisory functions at a national level (federal government, federal states (Länder)), and at an international level (World Health Organization, European Medicines Agency, European Commission, Council of Europe etc.).

Weitere Informationen:

http://www.ncbi.nlm.nih.gov/pubmed/?term=World+Health+Organization+International... - Abstract
http://aem.asm.org/content/early/2015/06/08/AEM.01150-15.full.pdf - Fulltext Accepted Manuscript

Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht Discovery of a Key Regulatory Gene in Cardiac Valve Formation
24.05.2017 | Universität Basel

nachricht Carcinogenic soot particles from GDI engines
24.05.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

Innovation 4.0: Shaping a humane fourth industrial revolution

17.05.2017 | Event News

 
Latest News

Devils Hole: Ancient Traces of Climate History

24.05.2017 | Earth Sciences

Discovery of a Key Regulatory Gene in Cardiac Valve Formation

24.05.2017 | Life Sciences

A CLOUD of possibilities: Finding new therapies by combining drugs

24.05.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>